| Year |
Citation |
Score |
| 2023 |
Jin WJ, Jagodinsky JC, Vera JM, Clark PA, Zuleger CL, Erbe AK, Ong IM, Le T, Tetreault K, Berg T, Rakhmilevich AL, Kim K, Newton MA, Albertini MR, Sondel PM, et al. NK cells propagate T cell immunity following in situ tumor vaccination. Cell Reports. 42: 113556. PMID 38096050 DOI: 10.1016/j.celrep.2023.113556 |
0.374 |
|
| 2022 |
Li Z, Ding Y, Liu J, Wang J, Mo F, Wang Y, Chen-Mayfield TJ, Sondel PM, Hong S, Hu Q. Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment. Nature Communications. 13: 1845. PMID 35387972 DOI: 10.1038/s41467-022-29388-0 |
0.307 |
|
| 2021 |
Bates PD, Rakhmilevich AL, Cho MM, Bouchlaka MN, Rao SL, Hales JM, Orentas RJ, Fry TJ, Gilles SD, Sondel PM, Capitini CM. Combining Immunocytokine and Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2 Murine Neuroblastoma. Frontiers in Immunology. 12: 668307. PMID 34489927 DOI: 10.3389/fimmu.2021.668307 |
0.327 |
|
| 2021 |
Patel RB, Hernandez R, Carlson P, Grudzinski J, Bates AM, Jagodinsky JC, Erbe A, Marsh IR, Arthur I, Aluicio-Sarduy E, Sriramaneni RN, Jin WJ, Massey C, Rakhmilevich AL, Vail D, ... ... Sondel PM, et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Science Translational Medicine. 13. PMID 34261797 DOI: 10.1126/scitranslmed.abb3631 |
0.329 |
|
| 2021 |
Pieper AA, Rakhmilevich AL, Spiegelman DV, Patel RB, Birstler J, Jin WJ, Carlson PM, Charych DH, Hank JA, Erbe AK, Overwijk WW, Morris ZS, Sondel PM. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice. Journal For Immunotherapy of Cancer. 9. PMID 34172518 DOI: 10.1136/jitc-2021-002715 |
0.355 |
|
| 2020 |
Baniel CC, Sumiec EG, Hank JA, Bates AM, Erbe AK, Pieper AA, Hoefges AG, Patel RB, Rakhmilevich AL, Morris ZS, Sondel PM. Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model. Journal For Immunotherapy of Cancer. 8. PMID 33115944 DOI: 10.1136/jitc-2020-001262 |
0.31 |
|
| 2020 |
Baniel CC, Heinze CM, Hoefges A, Sumiec EG, Hank JA, Carlson PM, Jin WJ, Patel RB, Sriramaneni RN, Gillies SD, Erbe AK, Schwarz CN, Pieper AA, Rakhmilevich AL, Sondel PM, et al. Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response. Frontiers in Immunology. 11: 1610. PMID 32849544 DOI: 10.3389/Fimmu.2020.01610 |
0.468 |
|
| 2020 |
Bishop MW, Hutson PR, Hank JA, Sondel PM, Furman WL, Meagher MM, Navid F, Santana VM. A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors. Mabs. 12: 1773751. PMID 32643524 DOI: 10.1080/19420862.2020.1773751 |
0.316 |
|
| 2020 |
Damodharan SN, Walker KL, Forsberg MH, McDowell KA, Bouchlaka MN, Drier DA, Sondel PM, DeSantes KB, Capitini CM. Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation. Cytotherapy. PMID 32536506 DOI: 10.1016/J.Jcyt.2020.05.001 |
0.335 |
|
| 2020 |
Goldberg JL, Navid F, Hank JA, Erbe AK, Santana V, Gan J, de Bie F, Javaid AM, Hoefges A, Merdler M, Carmichael L, Kim K, Bishop MW, Meager MM, Gillies SD, ... ... Sondel PM, et al. Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma. Journal For Immunotherapy of Cancer. 8. PMID 32169872 DOI: 10.1136/Jitc-2020-000590 |
0.357 |
|
| 2020 |
Yang RK, Kuznetsov IB, Ranheim EA, Wei JS, Sindiri S, Gryder BE, Gangalapudi V, Song YK, Patel V, Hank JA, Zuleger CL, Erbe AK, Morris ZS, Quale R, Kim K, ... ... Sondel PM, et al. Outcome-related signatures identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated After Starting Hu14.18-IL2. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32152202 DOI: 10.1158/1078-0432.Ccr-19-3294 |
0.599 |
|
| 2020 |
Pearson ADJ, Rossig C, Lesa G, Diede SJ, Weiner S, Anderson J, Gray J, Geoerger B, Minard-Colin V, Marshall LV, Smith M, Sondel P, Bajars M, Baldazzi C, Barry E, et al. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. European Journal of Cancer (Oxford, England : 1990). 127: 52-66. PMID 31986450 DOI: 10.1016/J.Ejca.2019.12.029 |
0.342 |
|
| 2020 |
Sondel PM. Abstract IA10: Activating innate and adaptive immunity to improve outcome for “cold” tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-Ia10 |
0.484 |
|
| 2020 |
Sumiec EG, Baniel CC, Bates AM, Emma S, Nystuen E, Rakhmilevich AL, Erbe AK, Paul P, Galipeau J, Sondel PM, Morris ZS. Abstract 902: Augmentation of anti-melanoma response by combining radiation-based in situ vaccination with GIFT4 B cell therapy Immunology. 80: 902-902. DOI: 10.1158/1538-7445.Am2020-902 |
0.443 |
|
| 2020 |
Brown RJ, Zangl L, Arthur I, Pieper A, Carlson PM, Castillo J, Sondel PM, Rakhmilevich A, Morris ZS, Patel RB. Abstract 4455: Combination of bempegaldesleukin and anti-CTLA-4 prevents metastatic dissemination after primary surgery or radiation therapy in a preclinical model of non-small cell lung cancer Immunology. 80: 4455-4455. DOI: 10.1158/1538-7445.Am2020-4455 |
0.406 |
|
| 2020 |
Heaster T, Esbona K, Sondel PM, Skala MC. Abstract 375: In vivo metabolic autofluorescence imaging of macrophage heterogeneity across normal and cancerous tissue Cancer Research. 80: 375-375. DOI: 10.1158/1538-7445.Am2020-375 |
0.322 |
|
| 2019 |
Voeller J, Erbe AK, Slowinski J, Rasmussen K, Carlson PM, Hoefges A, VandenHeuvel S, Stuckwisch A, Wang X, Gillies SD, Patel RB, Farrel A, Rokita JL, Maris J, Hank JA, ... ... Sondel PM, et al. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. Journal For Immunotherapy of Cancer. 7: 344. PMID 31810498 DOI: 10.1186/S40425-019-0823-6 |
0.383 |
|
| 2019 |
Shusterman S, Naranjo A, Van Ryn C, Hank JA, Parisi MT, Shulkin BL, London WB, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM, Servaes S. Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: A Children's Oncology Group phase II study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31358541 DOI: 10.1158/1078-0432.Ccr-19-0798 |
0.441 |
|
| 2019 |
Voeller J, Sondel PM. Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology. 41: 163-169. PMID 30897608 DOI: 10.1097/Mph.0000000000001369 |
0.366 |
|
| 2019 |
Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, ... ... Sondel PM, et al. Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. Journal For Immunotherapy of Cancer. 7: 70. PMID 30871628 DOI: 10.1186/S40425-019-0538-8 |
0.368 |
|
| 2019 |
Hernandez R, Walker KL, Grudzinski JJ, Aluicio-Sarduy E, Patel R, Zahm CD, Pinchuk AN, Massey CF, Bitton AN, Brown RJ, Sondel PM, Morris ZS, Engle JW, Capitini CM, Weichert JP. Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's Lymphoma. Communications Biology. 2: 79. PMID 30820474 DOI: 10.1038/s42003-019-0327-4 |
0.314 |
|
| 2019 |
Ayuso JM, Truttschel R, Gong MM, Humayun M, Virumbrales-Munoz M, Vitek R, Felder M, Gillies SD, Sondel P, Wisinski KB, Patankar M, Beebe DJ, Skala MC. Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. Oncoimmunology. 8: 1553477. PMID 30723584 DOI: 10.1080/2162402X.2018.1553477 |
0.446 |
|
| 2019 |
Felder M, Kapur A, Rakhmilevich AL, Qu X, Sondel PM, Gillies SD, Connor J, Patankar MS. MUC16 suppresses human and murine innate immune responses. Gynecologic Oncology. PMID 30626487 DOI: 10.1016/J.Ygyno.2018.12.023 |
0.349 |
|
| 2019 |
Zangl L, Pieper A, Arthur I, Brown R, Rakhmilevich A, Sondel P, Morris Z, Patel R. External Beam Radiotherapy Required for Tumor Regression When Using CpG-Oligodeoxynucleotide and Anti-OX40 in an Immunologically Cold Tumor Model International Journal of Radiation Oncology*Biology*Physics. 105: S88. DOI: 10.1016/J.Ijrobp.2019.06.560 |
0.369 |
|
| 2018 |
Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, Neuman H, Hartig G, Weigel T, Mahvi D, Henry MB, Quale R, McFarland T, Gan J, Carmichael L, ... ... Sondel PM, et al. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunology, Immunotherapy : Cii. PMID 30073390 DOI: 10.1007/S00262-018-2223-Z |
0.587 |
|
| 2018 |
Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, ... Sondel PM, et al. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Frontiers in Immunology. 9: 1355. PMID 29967609 DOI: 10.3389/Fimmu.2018.01355 |
0.331 |
|
| 2018 |
Morris ZS, Guy EI, Werner LR, Carlson PM, Heinze CM, Kler JS, Busche SM, Jaquish AA, Sriramaneni RN, Carmichael L, Loibner H, Gillies SD, Korman AJ, Erbe AK, Hank JA, ... ... Sondel PM, et al. Tumor-specific inhibition of in situ vaccination by distant untreated tumor sites. Cancer Immunology Research. PMID 29748391 DOI: 10.1158/2326-6066.Cir-17-0353 |
0.334 |
|
| 2018 |
Diccianni MB, Mielke J, Williams R, Messer K, Ozkaynak F, Gilman AL, Naranjo A, London W, Sondel PM, Park J, Yu AL. Abstract LB-300: Natural antibodies to non-human glycans Neu5Gc and alpha-gal correlate with outcome of high-risk neuroblastoma patients treated with dinutuximab on COG ANBL0032 and ANBL0931 Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-300 |
0.349 |
|
| 2017 |
Rakhmilevich AL, Felder M, Lever L, Slowinski J, Rasmussen K, Hoefges A, Van De Voort TJ, Loibner H, Korman AJ, Gillies SD, Sondel PM. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model. Journal of Immunology (Baltimore, Md. : 1950). PMID 28062694 DOI: 10.4049/jimmunol.1601255 |
0.365 |
|
| 2017 |
Baniel C, Hank JA, Guy EI, Gillies SD, Korman AJ, Loibner H, Rakhmilevich AL, Harari PM, Sondel PM, Morris ZS. In situ vaccination with local radiation and intratumoral immunocytokine to elicit a tumor-specific memory B-cell response. Journal of Clinical Oncology. 35: 69-69. DOI: 10.1200/Jco.2017.35.7_Suppl.69 |
0.434 |
|
| 2017 |
Desantes K, Maris JM, McDowell K, Mackall C, Shankar S, Vasselli J, Chen F, Loo D, Moore PA, Wigginton JM, Sondel PM. A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors. Journal of Clinical Oncology. 35: TPS2596-TPS2596. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps2596 |
0.418 |
|
| 2017 |
Erbe AK, Wang W, Carmichael L, Kim K, Reville PK, London WB, Hank JA, Diccianni MB, Naranjo A, Hogarty M, Park JR, Yu AL, Sondel PM. Abstract LB-048: Impact of KIR/KIR ligand genotype for neuroblastoma patients in a Phase 3 COG immunotherapy trial Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-048 |
0.317 |
|
| 2016 |
Erbe AK, Wang W, Goldberg J, Gallenberger M, Kim K, Carmichael L, Hess D, Mendonca EA, Song Y, Hank JA, Cheng SC, Signoretti S, Atkins M, Carlson A, Mier JW, ... ... Sondel PM, et al. FCGR Polymorphisms Influence Response to IL-2 in Metastatic Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27742794 DOI: 10.1158/1078-0432.Ccr-16-1874 |
0.456 |
|
| 2016 |
Horta ZP, Goldberg JL, Sondel PM. Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy. 8: 1097-117. PMID 27485082 DOI: 10.2217/imt-2016-0021 |
0.3 |
|
| 2016 |
Albertini MR, Ranheim EA, Zuleger CL, Sondel PM, Hank JA, Bridges A, Newton MA, McFarland T, Collins J, Clements E, Henry MB, Neuman HB, Weber S, Whalen G, Galili U. Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma. Cancer Immunology, Immunotherapy : Cii. PMID 27207605 DOI: 10.1007/s00262-016-1846-1 |
0.401 |
|
| 2016 |
Morris ZS, Guy EI, Francis DM, Gressett MM, Werner LR, Carmichael L, Yang RK, Armstrong EA, Huang S, Navid F, Gillies SD, Korman AJ, Hank JA, Rakhmilevich AL, Harari PM, ... Sondel PM, et al. In situ tumor vaccination by combining local radiation and tumor-specific antibody or immunocytokine treatments. Cancer Research. PMID 27197149 DOI: 10.1158/0008-5472.Can-15-2644 |
0.606 |
|
| 2016 |
Erbe AK, Wang W, Carmichael L, Kim K, Mendonca EA, Song Y, Hess D, London WB, Hank JA, Dicciani MB, Reisfeld RA, Gillies SD, Hogarty MD, Maris JM, Park JR, ... ... Sondel PM, et al. Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial. Journal of Clinical Oncology. 34: e14014-e14014. DOI: 10.1200/Jco.2016.34.15_Suppl.E14014 |
0.324 |
|
| 2016 |
Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes S, Dicciani MB, Sondel PM, Maris JM, Park JR, Bagatell R. Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Children’s Oncology Group (COG). Journal of Clinical Oncology. 34: 10502-10502. DOI: 10.1200/Jco.2016.34.15_Suppl.10502 |
0.323 |
|
| 2016 |
Furman WL, Federico SM, McCarville MB, Davidoff AM, Krasin MJ, Wu J, Brennan RC, Bishop MW, Santana VM, Bahrami A, Anthony G, Gillies SD, Sondel PM, Leung WH, Pappo AS. Improved clinical responses with the concomitant use of an anti-GD2 monoclonal antibody and chemotherapy in newly diagnosed children with high-risk (HR) neuroblastoma (NB): Preliminary results of a phase II study. Journal of Clinical Oncology. 34: 10501-10501. DOI: 10.1200/Jco.2016.34.15_Suppl.10501 |
0.309 |
|
| 2016 |
Werner LR, Gressett M, Riegert M, Huang S, Kern JG, Erbe A, Harari PM, Sondel PM, Morris ZS. Abstract 4013: Transcriptionally mediated effects of radiation on the expression of immune susceptibility markers in murine and human melanoma Cancer Research. 76: 4013-4013. DOI: 10.1158/1538-7445.Am2016-4013 |
0.427 |
|
| 2016 |
Morris ZS, Guy E, Francis D, Gressett MM, Armstrong EA, Huang S, Werner LR, Gillies SD, Korman A, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM. Abstract 4011: Effectivein situimmunization via local radiation therapy (RT) and tumor-specific immunocytokine (IC): Suppression from distant tumor is blocked by RT or Treg-depleting CTLA-4 antibody Cancer Research. 76: 4011-4011. DOI: 10.1158/1538-7445.Am2016-4011 |
0.437 |
|
| 2015 |
Shusterman S, London WB, Hank JA, Parisi MT, Shulkin BL, Servaes S, Naranjo A, Shimada H, Gan J, Gillies S, Maris JM, Park JR, Sondel PM. A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children’s Oncology Group study. Journal of Clinical Oncology. 33: 10017-10017. DOI: 10.1200/Jco.2015.33.15_Suppl.10017 |
0.415 |
|
| 2015 |
Rakhmilevich A, Felder M, Lever L, Van De Voort T, Korman AJ, Gillies SD, Sondel PM. Activation of innate and adaptive immunity as an effective combined strategy for cancer immunotherapy Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P370 |
0.458 |
|
| 2015 |
Morris ZS, Guy EI, Francis DM, Gressett MM, Armstrong EA, Huang S, Gillies SD, Korman AJ, Hank JA, Rakhmilevich AL, Harari PM, Sondel PM. Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P308 |
0.417 |
|
| 2015 |
Erbe AK, Wang W, Kim KM, Carmichael L, Gallendberger M, Hess D, Mendonca EA, Song Y, Hank JA, Chen S, Signoretti S, Atkins MB, Carlson A, Mier J, Panka D, ... ... Sondel PM, et al. Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2) Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P300 |
0.414 |
|
| 2015 |
Morishima C, McNeel DG, Patel MR, Kohrt HE, Waldmann TA, Thompson JA, Conlon KC, Sondel PM, Wakelee HA, Apodaca MC, Fling SP, Disis ML, Creekmore SP, Miller JS. CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P203 |
0.395 |
|
| 2014 |
Mandell RB, Sondel PM. Allele-specific alien-driven diversity, immune responsiveness and MHC-restriction. Immunology Today. 6: 321-3. PMID 25291000 DOI: 10.1016/0167-5699(85)90126-4 |
0.323 |
|
| 2014 |
Albertini MR, Ranheim E, Hank JA, Zuleger C, McFarland T, Collins J, Clements E, Weber SM, Weigel T, Neuman HB, Hartig GK, Mahvi D, Henry M, Gan J, Yang R, ... ... Sondel PM, et al. A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma. Journal of Clinical Oncology. 32: 9044-9044. DOI: 10.1200/Jco.2014.32.15_Suppl.9044 |
0.586 |
|
| 2014 |
Ozkaynak MF, Gilman AL, Yu AL, London WB, Sondel PM, Smith MA, Seeger R, Reynolds CP, Maris JM, Park JR. A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: A Children's Oncology Group study. Journal of Clinical Oncology. 32: 10044-10044. DOI: 10.1200/Jco.2014.32.15_Suppl.10044 |
0.346 |
|
| 2014 |
Morris ZS, Guy E, Francis D, Gressett M, Yang R, Rakhmilevich A, Hank J, Gillies S, Harari P, Sondel P. In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P160 |
0.637 |
|
| 2014 |
Perez Horta Z, Gillies S, Boyden M, Hank J, Rahkmilevich A, Sondel P. Evaluation of novel immunocytokines that preferentially target high or intermediate affinity IL-2 receptors Journal For Immunotherapy of Cancer. 2: P118. DOI: 10.1186/2051-1426-2-S3-P118 |
0.39 |
|
| 2014 |
Zuleger CL, Sondel PM, Hank JA, Ranheim EA, McFarland TA, Collins J, Clements E, Whalen G, Galili U, Albertini MR. Abstract 2538: Immune responses to common melanoma-associated antigens following intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma Cancer Research. 74: 2538-2538. DOI: 10.1158/1538-7445.Am2014-2538 |
0.402 |
|
| 2013 |
Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunology, Immunotherapy : Cii. 62: 1303-13. PMID 23661160 DOI: 10.1007/S00262-013-1430-X |
0.611 |
|
| 2013 |
Van De Voort TJ, Felder MA, Yang RK, Sondel PM, Rakhmilevich AL. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 29-40. PMID 23211623 DOI: 10.1097/CJI.0b013e3182780f61 |
0.566 |
|
| 2013 |
Alderson KL, Luangrath M, Elsenheimer MM, Gillies SD, Navid F, Rakhmilevich AL, Sondel PM. Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG. Cancer Immunology, Immunotherapy : Cii. 62: 665-75. PMID 23151945 DOI: 10.1007/S00262-012-1372-8 |
0.491 |
|
| 2013 |
Nettenstrom L, Alderson K, Raschke EE, Evans MD, Sondel PM, Olek S, Seroogy CM. An optimized multi-parameter flow cytometry protocol for human T regulatory cell analysis on fresh and viably frozen cells, correlation with epigenetic analysis, and comparison of cord and adult blood. Journal of Immunological Methods. 387: 81-8. PMID 23058673 DOI: 10.1016/J.Jim.2012.09.014 |
0.322 |
|
| 2013 |
Erbe AK, Wang W, Grzywacz B, Ranheim EA, Hank JA, Kim K, Carmichael L, Seo S, Mendonca EA, Song Y, Hong F, Gascoyne RD, Paietta E, Horning SH, Kahl B, ... Sondel PM, et al. Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P243 |
0.345 |
|
| 2013 |
Grzywacz B, Erbe AK, Wang W, Ranheim EA, Hank JA, Kim K, Carmichael L, Seo S, Mendonca EA, Song Y, Hong F, Gascoyne RD, Paietta E, Horning SJ, Kahl BS, ... Sondel PM, et al. Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma Blood. 122: 507-507. DOI: 10.1182/Blood.V122.21.507.507 |
0.331 |
|
| 2013 |
Voort TVD, Sondel P, Felder M, Young R, Kalogriopoulos N, Rakhmilevich A. Abstract A33: Combination immunotherapy with anti-CD40 mAb and MPL results in T cell-independent antitumor effects against B16 melanoma in mice. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-A33 |
0.414 |
|
| 2012 |
Sondel PM, Gillies SD. Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. Antibodies (Basel, Switzerland). 1: 149-171. PMID 24634778 DOI: 10.3390/Antib1020149 |
0.445 |
|
| 2012 |
Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. Journal of Immunology (Baltimore, Md. : 1950). 189: 2656-64. PMID 22844125 DOI: 10.4049/Jimmunol.1200934 |
0.591 |
|
| 2012 |
Rakhmilevich AL, Alderson KL, Sondel PM. T-cell-independent antitumor effects of CD40 ligation. International Reviews of Immunology. 31: 267-78. PMID 22804571 DOI: 10.3109/08830185.2012.698337 |
0.388 |
|
| 2012 |
Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, Sondel PM. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunology, Immunotherapy : Cii. 61: 2261-71. PMID 22678096 DOI: 10.1007/S00262-012-1286-5 |
0.368 |
|
| 2012 |
Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, Hank JA, Sondel PM. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Frontiers in Pharmacology. 3: 91. PMID 22623917 DOI: 10.3389/Fphar.2012.00091 |
0.438 |
|
| 2012 |
Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, Felder MA, Yang RK, Kalogriopoulos NA, Koslov DS, Van Rooijen N, Sondel PM. Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunology, Immunotherapy : Cii. 61: 1683-97. PMID 22392192 DOI: 10.1007/S00262-012-1236-2 |
0.646 |
|
| 2012 |
Albertini MR, Hank JA, Gadbaw BC, Kostlevy J, Haldeman J, Gan J, Kim K, Eickhoff JC, Gillies S, Sondel PM. Immune monitoring of phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Journal of Clinical Oncology. 30: e19047-e19047. DOI: 10.1200/Jco.2012.30.15_Suppl.E19047 |
0.406 |
|
| 2012 |
Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Abstract 1538: Enhanced antitumor effects of intratumoral (IT) hu14.18-IL2 immunocytokine (IC) compared to intravenous (IV) hu14.18-IL2 are distinguished by increased activated tumor infiltrating lymphocytes (TILs) and IC retention Cancer Research. 72: 1538-1538. DOI: 10.1158/1538-7445.Am2012-1538 |
0.456 |
|
| 2011 |
Navid F, Barfield RC, Handgretinger R, Sondel PM, Shulkin BL, Kaufman R, Billups C, Wu J, Furman WL, McGregor LM, Otto M, Gillies S, Santana VM. A novel anti-GD2 monoclonal antibody (mAb), hu14.18K322A, in children with refractory or recurrent neuroblastoma: Early-phase evaluation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 9523. PMID 28019789 DOI: 10.1200/Jco.2011.29.15_Suppl.9523 |
0.366 |
|
| 2011 |
Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM. Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy. International Immunopharmacology. 11: 1877-86. PMID 21854876 DOI: 10.1016/J.Intimp.2011.07.019 |
0.799 |
|
| 2011 |
Gubbels JA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, Connor J. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunology, Immunotherapy : Cii. 60: 1789-800. PMID 21792658 DOI: 10.1007/S00262-011-1072-9 |
0.362 |
|
| 2011 |
Lange BJ, Yang RK, Gan J, Hank JA, Sievers EL, Alonzo TA, Gerbing RB, Sondel PM. Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatric Blood & Cancer. 57: 398-405. PMID 21681921 DOI: 10.1002/Pbc.22966 |
0.551 |
|
| 2011 |
Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. Journal of Biomedicine & Biotechnology. 2011: 379123. PMID 21660134 DOI: 10.1155/2011/379123 |
0.339 |
|
| 2011 |
Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM. The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunology, Immunotherapy : Cii. 60: 731-8. PMID 21340652 DOI: 10.1007/S00262-011-0971-0 |
0.771 |
|
| 2011 |
Buhtoiarov IN, Neal ZC, Gan J, Buhtoiarova TN, Patankar MS, Gubbels JA, Hank JA, Yamane B, Rakhmilevich AL, Reisfeld RA, Gillies SD, Sondel PM. Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting. Journal of Leukocyte Biology. 89: 625-38. PMID 21248148 DOI: 10.1189/Jlb.0710422 |
0.342 |
|
| 2011 |
Johnson EE, Buhtoiarov IN, Baldeshwiler MJ, Felder MA, Van Rooijen N, Sondel PM, Rakhmilevich AL. Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. Journal of Immunotherapy (Hagerstown, Md. : 1997). 34: 76-84. PMID 21150715 DOI: 10.1097/CJI.0b013e318200b28a |
0.318 |
|
| 2011 |
McDowell KA, Hank JA, Sondel PM. Abstract 1809: Stimulation of antibody dependent cell-mediated cytotoxicity by interleukin-15 is equivalent to interleukin-2 Cancer Research. 71: 1809-1809. DOI: 10.1158/1538-7445.Am2011-1809 |
0.403 |
|
| 2011 |
Connor J, Buhtoiarov I, Gillies S, Gubbels J, Hank J, Sondel P, Kapur A, Patankar M. Ab-IL2 fusion proteins mediate NK cell immune synapse formation in epithelial ovarian cancer by polarizing CD25 to the target cell–effector cell interface Gynecologic Oncology. 120: S42. DOI: 10.1016/J.Ygyno.2010.12.103 |
0.365 |
|
| 2010 |
Galili U, Albertini MR, Sondel PM, Wigglesworth K, Sullivan M, Whalen GF. In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids. Cancers. 2: 773-93. PMID 23087817 DOI: 10.3390/cancers2020773 |
0.322 |
|
| 2010 |
Yang RK, Sondel PM. Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs of the Future. 35: 665. PMID 21037966 |
0.536 |
|
| 2010 |
Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, ... ... Sondel PM, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Research. 70: 9554-61. PMID 20935224 DOI: 10.1158/0008-5472.Can-10-2211 |
0.58 |
|
| 2010 |
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, ... ... Sondel PM, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. The New England Journal of Medicine. 363: 1324-34. PMID 20879881 DOI: 10.1056/Nejmoa0911123 |
0.341 |
|
| 2010 |
Soto BL, Hank JA, Polans AS, Voort Tvd, Rakhmilevich AL, Seo S, Kuyungmann K, Gillies SD, Sondel PM. Abstract LB-325: Antitumor effect of resveratrol combined with immunocytokine immunotherapy Immunology. 70. DOI: 10.1158/1538-7445.Am10-Lb-325 |
0.746 |
|
| 2009 |
Johnson EE, Yamane BH, Buhtoiarov IN, Lum HD, Rakhmilevich AL, Mahvi DM, Gillies SD, Sondel PM. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4875-84. PMID 19638464 DOI: 10.1158/1078-0432.Ccr-09-0110 |
0.584 |
|
| 2009 |
Wu QL, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim EA. Tumoricidal effects of activated macrophages in a mouse model of chronic lymphocytic leukemia. Journal of Immunology (Baltimore, Md. : 1950). 182: 6771-8. PMID 19454672 DOI: 10.4049/Jimmunol.0801847 |
0.366 |
|
| 2008 |
Albertini MR, Hank JA, Schalch H, Kostlevy J, Cassaday R, Gan J, Kim K, Clements B, Gillies SD, Sondel PM. Phase II trial of hu14.18-IL2 (EMD 273063) for patients with metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 9039. PMID 27950746 DOI: 10.1200/Jco.2008.26.15_Suppl.9039 |
0.38 |
|
| 2008 |
Meany HJ, Seibel NL, Sun J, Finklestein JZ, Sato J, Kelleher J, Sondel P, Reaman G. Phase 2 Trial of Recombinant Tumor Necrosis Factor-α in Combination With Dactinomycin in Children With Recurrent Wilms Tumor Journal of Immunotherapy. 31: 679-683. PMID 18600176 DOI: 10.1097/Cji.0B013E3181826D72 |
0.432 |
|
| 2008 |
Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM. Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunology, Immunotherapy : Cii. 57: 1891-902. PMID 18438664 DOI: 10.1007/S00262-008-0519-0 |
0.63 |
|
| 2008 |
Rakhmilevich AL, Buhtoiarov IN, Malkovsky M, Sondel PM. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunology, Immunotherapy : Cii. 57: 1151-60. PMID 18214476 DOI: 10.1007/S00262-007-0447-4 |
0.357 |
|
| 2008 |
Shusterman S, London WB, Gillies SD, Hank JA, Voss S, Seeger RC, Hecht T, Reisfeld RA, Maris JM, Sondel PM. Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children’s Oncology Group (COG) phase II study Journal of Clinical Oncology. 26: 3002-3002. DOI: 10.1200/Jco.2008.26.15_Suppl.3002 |
0.404 |
|
| 2008 |
Lange B, Yang RK, Gan J, Hank JA, Sievers E, Gerbing R, Alonzo T, Sondel PM. Clinical and Serologic Interleukin 2 Receptor α Response to Interleukin-2 in CCG-2961, a Ranomized Phase 3 Trial for Pediatric Acute Myeloid Leukemia. Blood. 112: 959-959. DOI: 10.1182/Blood.V112.11.959.959 |
0.565 |
|
| 2008 |
Cho CS, Singh A, Rakhmilevich A, Seroogy CM, Suresh M, Sondel PM. QS317. Cancer Induces Immune Suppression Proportional to Extent of Tumor Burden Journal of Surgical Research. 144: 392. DOI: 10.1016/J.Jss.2007.12.568 |
0.367 |
|
| 2007 |
Mahvi DM, Henry MB, Albertini MR, Weber S, Meredith K, Schalch H, Rakhmilevich A, Hank J, Sondel P. Intratumoral injection of IL-12 plasmid DNA--results of a phase I/IB clinical trial. Cancer Gene Therapy. 14: 717-23. PMID 17557109 DOI: 10.1038/Sj.Cgt.7701064 |
0.331 |
|
| 2007 |
Neal ZC, Sondel PM, Bates MK, Gillies SD, Herweijer H. Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory. Cancer Immunology, Immunotherapy : Cii. 56: 1765-74. PMID 17426968 DOI: 10.1007/s00262-007-0320-5 |
0.32 |
|
| 2006 |
Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology. 118: 261-70. PMID 16771862 DOI: 10.1111/J.1365-2567.2006.02366.X |
0.581 |
|
| 2006 |
Lum HD, Buhtoiarov IN, Schmidt BE, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. Journal of Leukocyte Biology. 79: 1181-92. PMID 16565324 DOI: 10.1189/Jlb.0405191 |
0.603 |
|
| 2006 |
Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J, Seeger RC, Matthay KK, Reynolds CP, Twist C, Krailo M, Adamson PC, Reisfeld RA, Gillies SD, Sondel PM, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1750-9. PMID 16551859 DOI: 10.1158/1078-0432.Ccr-05-2000 |
0.414 |
|
| 2006 |
Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. Journal of Immunology (Baltimore, Md. : 1950). 176: 309-18. PMID 16365423 DOI: 10.4049/Jimmunol.176.1.309 |
0.626 |
|
| 2006 |
Choi BS, Sondel PM, Hank JA, Schalch H, Gan J, King DM, Kendra K, Mahvi D, Lee LY, Kim K, Albertini MR. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunology, Immunotherapy : Cii. 55: 761-74. PMID 16187086 DOI: 10.1007/S00262-005-0069-7 |
0.358 |
|
| 2006 |
Cassaday R, Sondel P, King D, Warner T, Bridges A, Gan J, Schalch H, Hank J, Mahvi D, Albertini M. Clinical and immunological analysis of melanoma patients receiving immunization using particle-mediated gene transfer of genes for gp100 and GM-CSF into uninvolved skin Journal of Clinical Oncology. 24: 13033-13033. DOI: 10.1200/Jco.2006.24.18_Suppl.13033 |
0.313 |
|
| 2005 |
Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. Journal of Immunology (Baltimore, Md. : 1950). 174: 6013-22. PMID 15879094 DOI: 10.4049/Jimmunol.174.10.6013 |
0.636 |
|
| 2005 |
Rakhmilevich A, Buhtoiarov IN, Lum HD, Malkovsky M, Sondel PM. CD40 Ligation In Vivo Induces T Cell Independent Antitumor Effects Even Against Immunogenic Tumors Journal of Immunotherapy. 28: 636-637. DOI: 10.1097/01.Cji.0000191025.82920.94 |
0.642 |
|
| 2005 |
Buhtoiarov I, Rakhmilevich A, Lum H, Berke G, Sondel P. Macrophages are Essential for Growth Control of Weakly Immunogenic Tumors During Immunotherapy With CpG Journal of Immunotherapy. 28: 636. DOI: 10.1097/01.Cji.0000191022.98168.A6 |
0.603 |
|
| 2004 |
Weber SM, Qi C, Neal Z, Sondel P, Mahvi DM. IL-12 cDNA direct injection: Antimetastatic effect from a single injection in a murine hepatic metastases model Journal of Surgical Research. 122: 210-217. PMID 15555620 DOI: 10.1016/J.Jss.2004.04.021 |
0.377 |
|
| 2004 |
King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, Mahvi D, Schiller JH, Warner T, Kim K, Eickhoff J, Kendra K, Reisfeld R, Gillies SD, Sondel P. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4463-73. PMID 15483010 DOI: 10.1200/Jco.2004.11.035 |
0.331 |
|
| 2004 |
Rakhmilevich AL, Hooper AT, Hicklin DJ, Sondel PM. Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. Molecular Cancer Therapeutics. 3: 969-76. PMID 15299079 |
0.365 |
|
| 2004 |
Neal ZC, Yang JC, Rakhmilevich AL, Buhtoiarov IN, Lum HE, Imboden M, Hank JA, Lode HN, Reisfeld RA, Gillies SD, Sondel PM. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4839-47. PMID 15269160 DOI: 10.1158/1078-0432.Ccr-03-0799 |
0.348 |
|
| 2004 |
Connor JP, Felder M, Hank J, Harter J, Gan J, Gillies SD, Sondel P. Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. Journal of Immunotherapy (Hagerstown, Md. : 1997). 27: 211-9. PMID 15076138 DOI: 10.1097/00002371-200405000-00005 |
0.429 |
|
| 2004 |
Neal ZC, Imboden M, Rakhmilevich AL, Kim KM, Hank JA, Surfus J, Dixon JR, Lode HN, Reisfeld RA, Gillies SD, Sondel PM. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunology, Immunotherapy : Cii. 53: 41-52. PMID 14504825 DOI: 10.1007/S00262-003-0435-2 |
0.487 |
|
| 2004 |
Buhtoiarov IN, Sondel PM, Berke G, Lum HE, Rakhmilevich AL. Anti-CD40 Monoclonal Antibody and CpG-ODN Synergize in Macrophage Activation: Implication for Cancer Immunotherapy Journal of Immunotherapy. 27: S49. DOI: 10.1097/00002371-200411000-00178 |
0.328 |
|
| 2004 |
Yang JC, Neal Z, Rakhmilevich A, Buhtoiarov I, Lum H, Imboden M, Hank J, Lode H, Reisfeld R, Gillies S, Sondel P. Addition of systemic IL2 increases effectiveness of hu14.18-IL2 immunocytokine therapy against NXS2 murine neuroblastoma Journal of the American College of Surgeons. 199: 54-55. DOI: 10.1016/J.Jamcollsurg.2004.05.112 |
0.667 |
|
| 2003 |
Sondel PM, Hank JA, Gan J, Neal Z, Albertini MR. Preclinical and clinical development of immunocytokines. Current Opinion in Investigational Drugs (London, England : 2000). 4: 696-700. PMID 12901228 |
0.314 |
|
| 2003 |
Imboden M, Shi F, Pugh TD, Freud AG, Thom NJ, Hank JA, Hao Z, Staelin ST, Sondel PM, Mahvi DM. Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study. Human Gene Therapy. 14: 1037-48. PMID 12885344 DOI: 10.1089/104303403322124765 |
0.357 |
|
| 2003 |
Hank JA, Surfus JE, Gan J, Ostendorf A, Gillies SD, Sondel PM. Determination of peak serum levels and immune response to the humanized anti-ganglioside antibody-interleukin-2 immunocytokine. Methods in Molecular Medicine. 85: 123-31. PMID 12710203 DOI: 10.1385/1-59259-380-1:123 |
0.317 |
|
| 2002 |
Shi F, Rakhmilevich AL, Heise CP, Oshikawa K, Sondel PM, Yang NS, Mahvi DM. Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Molecular Cancer Therapeutics. 1: 949-57. PMID 12481417 |
0.331 |
|
| 2002 |
Mahvi DM, Pharo L, Gan J, Heisey D, Warner T, Sondel PM, Shi FS, Yang NS, Weber S, Hank J, Albertini M, Schiller J, Schalch H, Larson M. Immunization by particle-mediated transfer of the granulocyte-macrophage colony-stimulating factor gene into autologous tumor cells in melanoma or sarcoma patients: Report of a phase I/IB study Human Gene Therapy. 13: 1711-1721. PMID 12396624 DOI: 10.1089/104303402760293556 |
0.432 |
|
| 2002 |
Li JH, Rosen D, Sondel P, Berke G. Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells. Immunology. 105: 267-77. PMID 11918688 DOI: 10.1046/J.1365-2567.2002.01380.X |
0.338 |
|
| 2002 |
Sondel PM, Hank JA. Antibody-directed, effector cell-mediated tumor destruction. Hematology/Oncology Clinics of North America. 15: 703-21. PMID 11676280 DOI: 10.1016/S0889-8588(05)70243-4 |
0.451 |
|
| 2001 |
Dinndorf P, Krailo M, Liu-Mares W, Frierdich S, Sondel P, Reaman G. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. Journal of Immunotherapy. 24: 511-516. PMID 11759074 DOI: 10.1097/00002371-200111000-00008 |
0.341 |
|
| 2001 |
Oshikawa K, Rakhmilevich AL, Shi F, Sondel PM, Yang NS, Mahvi DM. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer Human Gene Therapy. 12: 149-160. PMID 11177552 DOI: 10.1089/104303401750061212 |
0.465 |
|
| 2001 |
Turner JG, Rakhmilevich AL, Burdelya L, Neal Z, Imboden M, Sondel PM, Yu H. Anti-CD40 antibody induces antitumor and antimetastatic effects: The role of NK cells Journal of Immunology. 166: 89-94. PMID 11123280 DOI: 10.4049/Jimmunol.166.1.89 |
0.398 |
|
| 2001 |
Monson NL, Fenske TJ, Wei S, Okragly AJ, Jong JLOd, Haak-Frendscho M, O’Shea J, Djeu J, Sondel PM. A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line Tf-1β2 Journal of Leukocyte Biology. 69: 419-425. DOI: 10.1189/Jlb.69.3.419 |
0.369 |
|
| 2000 |
Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 4077-85. PMID 11118469 DOI: 10.1200/Jco.2000.18.24.4077 |
0.316 |
|
| 2000 |
Rakhmilevich AL, Janssen K, Hao Z, Sondel PM, Yang NS. Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell- independent mechanism Cancer Gene Therapy. 7: 826-838. PMID 10880012 DOI: 10.1038/Sj.Cgt.7700176 |
0.487 |
|
| 1999 |
Oshikawa K, Shi F, Rakhmilevich AL, Sondel PM, Mahvi DM, Yang NS. Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β converting enzyme cDNA Proceedings of the National Academy of Sciences of the United States of America. 96: 13351-13356. PMID 10557324 DOI: 10.1073/Pnas.96.23.13351 |
0.412 |
|
| 1999 |
Kendra K, Gan J, Ricci M, Surfus J, Shaker A, Super M, Frost JD, Rakhmilevich A, Hank JA, Gillies SD, Sondel PM. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunology, Immunotherapy : Cii. 48: 219-29. PMID 10478638 DOI: 10.1007/S002620050569 |
0.33 |
|
| 1999 |
de Jong JL, Farner NL, Sondel PM. Distinctions in lymphocyte responses to IL-2 and IL-15 reflect differential ligand binding interactions with the IL-2Rbeta chain and suggest differential roles for the IL-2Ralpha and IL-15Ralpha subunits. Cytokine. 10: 920-30. PMID 10049515 DOI: 10.1006/Cyto.1998.0377 |
0.336 |
|
| 1999 |
Gan J, Kendra K, Ricci M, Hank JA, Gillies SD, Sondel PM. Specific Enzyme-Linked Immunosorbent Assays for Quantitation of Antibody-Cytokine Fusion Proteins Clinical Diagnostic Laboratory Immunology. 6: 236-242. DOI: 10.1128/Cdli.6.2.236-242.1999 |
0.376 |
|
| 1998 |
Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Liu-Mares W, Feig SA. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 914-9. PMID 9508173 DOI: 10.1200/Jco.1998.16.3.914 |
0.342 |
|
| 1997 |
Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer. 80: 317-33. PMID 9217046 DOI: 10.1002/(Sici)1097-0142(19970715)80:2<317::Aid-Cncr21>3.0.Co;2-W |
0.393 |
|
| 1997 |
Farner NL, Gan J, de Jong JL, Leary TP, Fenske TS, Buckley P, Dunlap S, Sondel PM. Alteration of the CD34+ Tf-1 beta cell line profile in response to long-term exposure to IL-15. Cytokine. 9: 316-27. PMID 9195130 DOI: 10.1006/Cyto.1996.0171 |
0.347 |
|
| 1996 |
Albertini MR, Gan J, Jaeger P, Hank JA, Storer B, Schell K, Rivest T, Surfus J, Reisfeld RA, Schiller JH, Sondel PM. Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 19: 278-95. PMID 8877722 DOI: 10.1097/00002371-199607000-00004 |
0.377 |
|
| 1996 |
Mahvi DM, Burkholder JK, Turner J, Culp J, Malter JS, Sondel PM, Yang NS. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: Implications for a clinically relevant tumor vaccine Human Gene Therapy. 7: 1535-1543. PMID 8864754 DOI: 10.1089/Hum.1996.7.13-1535 |
0.437 |
|
| 1996 |
Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, Schiller JH, Sondel PM. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody- dependent cellular cytotoxicity with in vitro and in vivo interleukin-2- activated effectors Journal of Immunotherapy. 19: 184-191. PMID 8811493 DOI: 10.1097/00002371-199605000-00003 |
0.413 |
|
| 1996 |
Rakhmilevich AL, Turner J, Ford MJ, Mccabe D, Sun WH, Sondel PM, Grota K, Yang NS. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors Proceedings of the National Academy of Sciences of the United States of America. 93: 6291-6296. PMID 8692808 DOI: 10.1073/Pnas.93.13.6291 |
0.452 |
|
| 1996 |
Helfand SC, Hank JA, Gan J, Sondel PM. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. Cellular Immunology. 167: 99-107. PMID 8548851 DOI: 10.1006/Cimm.1996.0012 |
0.408 |
|
| 1996 |
Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, Sondel PM. ACTIVATION OF HUMAN EFFECTOR CELLS BY A TUMOR REACTIVE RECOMBINANT ANTI-GANGLIOSIDE GD2 INTERLEUKIN-2 FUSION PROTEIN Journal of Immunotherapy. 19: 463. DOI: 10.1097/00002371-199611000-00039 |
0.42 |
|
| 1995 |
Mahvi DM, Madsen JA, Witt PL, Sondel PM. Interferon α enhances expression of TAG-72 and carcinoembryonic antigen in patients with primary colorectal cancer Cancer Immunology Immunotherapy. 40: 311-314. PMID 7600563 DOI: 10.1007/Bf01519631 |
0.429 |
|
| 1995 |
Helfand S, Modiano J, Moore P, Soergel S, MacWilliams P, Dubielzig R, Hank J, Gelfand E, Sondel P. Functional interleukin-2 receptors are expressed on natural killer-like leukemic cells from a dog with cutaneous lymphoma Blood. 86: 636-645. DOI: 10.1182/Blood.V86.2.636.Bloodjournal862636 |
0.39 |
|
| 1994 |
Hank JA, Albertini MR, Schiller J, Sondel PM. Activation of multiple effector mechanisms to enhance tumor immunotherapy. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 14: 329-35. PMID 8280716 DOI: 10.1097/00002371-199311000-00013 |
0.486 |
|
| 1994 |
Kaur I, de Jong J, Schell K, Hank J, Fisch P, Sondel PM. Human peripheral gamma delta T cells are stimulated by Daudi Burkitt's lymphoma and not by any other Burkitt's lymphoma tested. Cellular Immunology. 156: 54-61. PMID 8200042 DOI: 10.1006/Cimm.1994.1152 |
0.332 |
|
| 1994 |
Helfand SC, Soergel SA, MacWilliams PS, Hank JA, Sondel PM. Clinical and immunological effects of human recombinant interleukin-2 given by repetitive weekly infusion to normal dogs. Cancer Immunology, Immunotherapy : Cii. 39: 84-92. PMID 8044833 DOI: 10.1007/Bf01525313 |
0.425 |
|
| 1994 |
Helfand SC, Soergel SA, Donner RL, Gan J, Hank JA, Lindstrom MJ, Sondel PM. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 16: 188-97. PMID 7834118 DOI: 10.1097/00002371-199410000-00003 |
0.444 |
|
| 1994 |
Helfand SC, Soergel SA, Modiano JF, Hank JA, Sondel PM. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro. Cancer Biotherapy. 9: 237-44. PMID 7820185 DOI: 10.1089/Cbr.1994.9.237 |
0.454 |
|
| 1994 |
Oettel K, Wesly O, Albertini M, Hank J, Iliopolis O, Sosman J, Voelkerding K, Wu S, Clark S, Sondel P. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient Blood. 83: 3390-3402. DOI: 10.1182/Blood.V83.11.3390.3390 |
0.303 |
|
| 1994 |
Helfand SC, Donner RL, Hank JA, Sondel PM. LYSIS OF HUMAN TUMOR CELL LINES BY CANINE COMPLEMENT PLUS MONOCLONAL ANTI-GANGLIOSIDE ANTIBODIES OR NATURAL CANINE XENOANTIBODIES Journal of Immunotherapy. 16: 237. DOI: 10.1097/00002371-199410000-00021 |
0.395 |
|
| 1993 |
Sondel PM. Biologic and immunologic approaches to comprehensive therapy for pediatric malignant conditions. Laboratory-clinical interaction. Cancer. 71: 3429-34. PMID 8490894 DOI: 10.1002/1097-0142(19930515)71:10+<3429::Aid-Cncr2820711749>3.0.Co;2-H |
0.327 |
|
| 1993 |
Yabe T, McSherry C, Bach FH, Fisch P, Schall RP, Sondel PM, Houchins JP. A multigene family on human chromosome 12 encodes natural killer-cell lectins. Immunogenetics. 37: 455-60. PMID 8436421 DOI: 10.1007/Bf00222470 |
0.3 |
|
| 1993 |
Gambacorti-Passerini C, Hank JA, Albertini MR, Borchert AA, Moore KH, Schiller JH, Bechhofer R, Borden EC, Storer B, Sondel PM. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer. Journal of Immunotherapy With Emphasis On Tumor Immunology : Official Journal of the Society For Biological Therapy. 13: 43-8. PMID 8435431 DOI: 10.1097/00002371-199301000-00006 |
0.415 |
|
| 1993 |
Mahvi DM, Carper SW, Storm FK, Teal SR, Sondel PM. Overexpression of 27-kDa heat-shock protein in MCF-7 breast cancer cells: effects on lymphocyte-mediated killing by natural killer and gamma delta T cells. Cancer Immunology, Immunotherapy : Cii. 37: 181-6. PMID 8334681 DOI: 10.1007/Bf01525433 |
0.308 |
|
| 1993 |
Albertini MR, Howard SP, Fisch P, Lindstrom MJ, Hank JA, Gould MN, Sondel PM. Modulation of Target-Cell culture conditions alters susceptibility to lymphocyte-mediated lysis Journal of Immunotherapy. 13: 243-251. PMID 8334108 DOI: 10.1097/00002371-199305000-00003 |
0.347 |
|
| 1992 |
Albertini MR, Gibson DF, Robinson SP, Howard SP, Tans KJ, Lindstrom MJ, Robinson RR, Tormey DC, Jordan VC, Sondel PM. Influence of estradiol and tamoxifen on susceptibility of human breast cancer cell lines to lysis by lymphokine-activated killer cells. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 11: 30-9. PMID 1734946 DOI: 10.1097/00002371-199201000-00004 |
0.336 |
|
| 1992 |
Albertini MR, Hank JA, Sondel PM. Strategies for improving antitumor activity utilizing IL-2: preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2. Biotherapy (Dordrecht, Netherlands). 4: 189-98. PMID 1599802 DOI: 10.1007/Bf02174205 |
0.406 |
|
| 1992 |
Roper M, Smith MA, Sondel PM, Gillespie A, Reaman GH, Hammond GD, Levitt D, Rosolen A, Colamonici OR, Neckers LM, Poplack DG. A Phase I Study of Interleukin-2 in Children with Cancer Journal of Pediatric Hematology/Oncology. 14: 305-311. DOI: 10.1097/00043426-199211000-00005 |
0.382 |
|
| 1992 |
Hank J, Albertini M, Gambacorti C, Wesly O, Schiller J, Sondel P. ANTI-CD3 PLUS IL-2 IN PATIENTS WITH CANCER Journal of Immunotherapy. 11: 127. DOI: 10.1097/00002371-199202000-00023 |
0.353 |
|
| 1992 |
Hank JA, Surfus J, Gan J, Hong R, Tans K, Reisfeld R, Ettinger L, Senger R, Reynolds P, Friedrich S, Bauer M, Wiersma S, Hammond D, Sondel PM. COMBINED IMMUNOLOGIC THERAPY WITH INTERLEUKIN-2 AND ANTI-GD-2 MONOCLONAL ANTIBODY 14.G2a INDUCES IN VIVO IMMUNOLOGIC CONDITIONS ABLE TO MEDIATE ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY (ADCC) IN VITRO, IN PEDIATRIC NEUROBLASTOMA PATIENTS Journal of Immunotherapy. 11: 126. DOI: 10.1097/00002371-199202000-00022 |
0.352 |
|
| 1991 |
Albertini MR, Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Bechhofer R, Storer B, Sondel PM. The influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer. 66: 2457-64. PMID 2249185 DOI: 10.1002/1097-0142(19901215)66:12<2457::Aid-Cncr2820661203>3.0.Co;2-L |
0.407 |
|
| 1991 |
Sosman JA, Hank JA, Moore KH, Borchert A, Schell K, Kohler PC, Goldstein D, Bechhofer R, Storer B, Albertini MR, Leung PE, Levitt D, Sondel PM. Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom Cancer Investigation. 9: 35-48. PMID 2012995 DOI: 10.3109/07357909109032798 |
0.411 |
|
| 1991 |
Cannon A, Hank JA, Sondel PM. BLT-esterase activity following in vitro and in vivo activation of human lymphocytes with interleukin-2. In vivo IL-2 induces BLT-esterase. Biotherapy (Dordrecht, Netherlands). 3: 253-60. PMID 1854594 DOI: 10.1007/Bf02171689 |
0.382 |
|
| 1991 |
Weil-Hillman G, Schell K, Segal DM, Hank JA, Sosman JA, Sondel PM. Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2: implications for combined in vivo treatment. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 10: 267-77. PMID 1834166 DOI: 10.1097/00002371-199108000-00005 |
0.44 |
|
| 1991 |
Sondel PM. Interleukin-2: prospects for lymphocyte-mediated destruction of pediatric malignancies. The Journal of Pediatrics. 118: S14-6. PMID 1825672 DOI: 10.1016/S0022-3476(05)82184-5 |
0.343 |
|
| 1991 |
Albertini MR, Nicklas JA, Chastenay BF, Hunter TC, Albertini RJ, Clark SS, Hank JA, Sondel PM. Analysis of T cell receptor beta and gamma genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patients. Cancer Immunology, Immunotherapy : Cii. 32: 325-30. PMID 1825620 DOI: 10.1007/Bf01789051 |
0.332 |
|
| 1991 |
Schiller JH, Lindstrom M, Witt PL, Hank JA, Mahvi D, Wagner RJ, Sondel P, Borden EC. Immunological effects of levamisole in vitro. Journal of Immunotherapy : Official Journal of the Society For Biological Therapy. 10: 297-306. PMID 1790137 DOI: 10.1097/00002371-199110000-00001 |
0.439 |
|
| 1991 |
Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Advances in Experimental Medicine and Biology. 294: 425-35. PMID 1722946 DOI: 10.1007/978-1-4684-5952-4_39 |
0.305 |
|
| 1991 |
Gambacorti-Passerini C, Hank JA, Borchert A, Moore K, Malkovska V, Sondel P. In vivo effects of multiple cycles of recombinant interleukin-2 (IL2) on peripheral granulocyte-macrophage hematopoietic progenitors circulating in the blood of cancer patients. Tumori. 77: 420-422. DOI: 10.1177/030089169107700509 |
0.363 |
|
| 1990 |
Sondel PM, Hank JA. Prospects for clinical cancer treatment using interleukin-2. Cancer Investigation. 7: 437-42. PMID 2695228 DOI: 10.3109/07357908909041374 |
0.415 |
|
| 1990 |
Borden EC, Sondel PM. Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer. 65: 800-14. PMID 2406003 DOI: 10.1002/1097-0142(19900201)65:3+<800::Aid-Cncr2820651328>3.0.Co;2-Y |
0.453 |
|
| 1990 |
Sedgwick JB, Frick WE, Sondel PM, Hank JA, Borden E, Busse WW. The appearance of hypodense eosinophils during interleukin-2 treatment. The Journal of Allergy and Clinical Immunology. 85: 557-66. PMID 2312991 DOI: 10.1016/0091-6749(90)90093-J |
0.371 |
|
| 1990 |
Hank JA, Weil-Hillman G, Surfus JE, Sosman JA, Sondel PM. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunology, Immunotherapy : Cii. 31: 53-9. PMID 2306756 DOI: 10.1007/Bf01742496 |
0.376 |
|
| 1990 |
Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RLH, Prieve A, Sosman JAA, Lam VA, Sondel PM. γ/δ cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis Journal of Experimental Medicine. 171: 1567-1579. PMID 2185329 DOI: 10.1084/Jem.171.5.1567 |
0.369 |
|
| 1990 |
Bridges AJ, Norback D, Fisch P, England D, Sondel P. T helper-cell leukemia/lymphoma: Presentation as an acute immune-mediated illness Journal of Clinical Immunology. 10: 61-70. PMID 2138165 DOI: 10.1007/Bf00917499 |
0.4 |
|
| 1990 |
Sosman J, Oettel K, Smith S, Hank J, Fisch P, Sondel P. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells Blood. 75: 2005-2016. DOI: 10.1182/Blood.V75.10.2005.Bloodjournal75102005 |
0.385 |
|
| 1989 |
Kohler PC, Hank JA, Moore KH, Storer B, Bechhofer R, Hong R, Sondel PM. Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion. Cancer Investigation. 7: 213-23. PMID 2790538 DOI: 10.3109/07357908909039840 |
0.38 |
|
| 1989 |
Sondel PM, Sosman JA, Hank JA, Kohler PC, Storer B. Tumor-infiltrating lymphocytes and interleukin-2 in melanomas. The New England Journal of Medicine. 320: 1418-9. PMID 2785641 DOI: 10.1056/NEJM198905253202115 |
0.31 |
|
| 1989 |
Sondel PM, Hank JA, Kohler PC, Sosman JA, Weil-Hillman G, Fisch P. The cellular immunotherapy of cancer: current and potential uses of interleukin-2. Critical Reviews in Oncology/Hematology. 9: 125-47. PMID 2663205 DOI: 10.1016/S1040-8428(89)80008-3 |
0.411 |
|
| 1989 |
Sosman JA, Oettel KR, Hank JA, Fisch P, Sondel PM. Specific recognition of human leukemic cells by allogeneic T cell lines. Transplantation. 48: 486-95. PMID 2571206 DOI: 10.1097/00007890-198909000-00027 |
0.381 |
|
| 1989 |
Chen BP, Lam V, Kraus EE, DeMars R, Sondel PM. Restriction of Epstein-Barr virus-specific cytotoxic T cells by HLA-A, -B, and -C molecules Human Immunology. 26: 137-147. PMID 2479624 DOI: 10.1016/0198-8859(89)90099-2 |
0.309 |
|
| 1989 |
Carlin JM, Borden EC, Sondel PM, Byrne GI. Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes. Journal of Leukocyte Biology. 45: 29-34. PMID 2463322 DOI: 10.1002/Jlb.45.1.29 |
0.352 |
|
| 1989 |
Fisch P, Weil-Hillman G, Uppenkamp M, Hank J, Chen B, Sosman J, Bridges A, Colamonici O, Sondel P. Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia Blood. 74: 343-353. DOI: 10.1182/blood.v74.1.343.bloodjournal741343 |
0.336 |
|
| 1989 |
Fisch P, Weil-Hillman G, Uppenkamp M, Hank J, Chen B, Sosman J, Bridges A, Colamonici O, Sondel P. Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemia Blood. 74: 343-353. DOI: 10.1182/Blood.V74.1.343.343 |
0.444 |
|
| 1988 |
Kohler PC, Hank JA, Minkoff DZ, Sondel PM. Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions. Cancer Immunology, Immunotherapy : Cii. 26: 74-82. PMID 3257904 DOI: 10.1007/Bf00199851 |
0.385 |
|
| 1988 |
Sosman JA, Kohler PC, Hank J, Moore KH, Bechhofer R, Storer B, Sondel PM. Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. Journal of the National Cancer Institute. 80: 60-3. PMID 3257526 DOI: 10.1093/Jnci/80.1.60 |
0.37 |
|
| 1988 |
Chen BP, DeMars R, Hank JA, Sondel PM. CD4+ proliferative T-cell clones reactive to autologous Epstein-Barr virus-transformed B cells (EBV-LCL) can be restricted by HLA class I molecules. Cellular Immunology. 115: 363-72. PMID 2842068 DOI: 10.1016/0008-8749(88)90188-8 |
0.314 |
|
| 1988 |
Sedgwick J, Frick W, Sondel P, Busse W. 161 The appearance of hypodense eosinophils (HE) durihg interleukin-2 (IL-2) treatmemt Journal of Allergy and Clinical Immunology. 81: 208. DOI: 10.1016/0091-6749(88)90397-1 |
0.32 |
|
| 1987 |
Chen BP, DeMars R, Sondel PM. Presentation of soluble antigen to human T cells by products of multiple HLA-linked loci: analysis of antigen presentation by a panel of cloned, autologous, HLA-mutant Epstein-Barr virus-transformed lymphoblastoid cell lines. Human Immunology. 18: 75-91. PMID 3542914 DOI: 10.1016/0198-8859(87)90114-5 |
0.319 |
|
| 1987 |
Chen BP, Malkovsky M, Hank JA, Sondel PM. Nonrestricted cytotoxicity mediated by interleukin 2-expanded leukocytes is inhibited by anti-LFA-1 monoclonal antibodies (MoAb) but potentiated by anti-CD3 MoAb Cellular Immunology. 110: 282-293. PMID 2961460 DOI: 10.1016/0008-8749(87)90123-7 |
0.4 |
|
| 1987 |
Burlingham WJ, Grailer A, Sparks-Mackety EM, Sondel PM, Sollinger HW. Improved renal allograft survival following donor-specific transfusions. II. In vitro correlates of early (DST-type) rejection episodes. Transplantation. 43: 41-6. PMID 2948309 DOI: 10.1097/00007890-198701000-00010 |
0.313 |
|
| 1987 |
Moen R, Horowitz S, Sondel P, Borcherding W, Trigg M, Billing R, Hong R. Immunologic reconstitution after haploidentical bone marrow transplantation for immune deficiency disorders: treatment of bone marrow cells with monoclonal antibody CT-2 and complement Blood. 70: 664-669. DOI: 10.1182/Blood.V70.3.664.Bloodjournal703664 |
0.345 |
|
| 1986 |
Reitnauer PJ, Brown LR, Hank JA, Sondel PM. Presentation of Candida albicans and purified protein derivative soluble antigens by Epstein-Barr virus-transformed human lymphoblastoid B-cell lines. Cellular Immunology. 99: 196-208. PMID 3019572 DOI: 10.1016/0008-8749(86)90228-5 |
0.365 |
|
| 1985 |
Kohler PC, Hank JA, Exten R, Minkoff DZ, Wilson DG, Sondel PM. Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial. Cancer. 55: 552-60. PMID 3155491 DOI: 10.1002/1097-0142(19850201)55:3<552::Aid-Cncr2820550314>3.0.Co;2-2 |
0.362 |
|
| 1985 |
Reitnauer PJ, DeMars R, Sondel PM. The proliferative immune response to autologous Epstein-Barr virus-transformed lymphoblastoid cells. I. Studies with HLA haplotype loss variants demonstrate a role for MHC-linked genes. Human Immunology. 13: 177-91. PMID 2989227 DOI: 10.1016/0198-8859(85)90010-2 |
0.308 |
|
| 1985 |
Schwartz BS, Reitnauer PJ, Hank JA, Sondel PM. A human T cell clone that mediates the monocyte procoagulant response to specific sensitizing antigen Journal of Clinical Investigation. 76: 1279-1282. PMID 2413073 DOI: 10.1172/Jci112085 |
0.365 |
|
| 1984 |
Sondel PM, Kohler PC, Hank JA, Bozdech MJ, Lieberman LM, Hong R, Albertini R, Exten RE. The in vivo distribution of indium-111 labeled in vitro alloactivated syngeneic lymphocytes in a patient with relapsed acute myelomonocytic leukemia: implications for adoptive chemoimmunotherapy. Leukemia Research. 8: 893-903. PMID 6387300 DOI: 10.1016/0145-2126(84)90110-3 |
0.363 |
|
| 1984 |
Robins HI, Dennis WH, Steeves RA, Sondel PM. A proposal for the addition of hyperthermia to treatment regimens for acute and chronic leukemia Journal of Clinical Oncology. 2: 1050-1056. PMID 6381656 DOI: 10.1200/Jco.1984.2.9.1050 |
0.311 |
|
| 1984 |
Hank JA, Sondel PM. Recognition of autologous lymphoblastoid cells by cloned human T cells: inhibition of cytotoxicity by anti-HLA antibody but not by antibody to Epstein-Barr virus induced cell surface antigen. Human Immunology. 9: 211-9. PMID 6201468 DOI: 10.1016/0198-8859(84)90026-0 |
0.374 |
|
| 1984 |
DeMars R, Chang CC, Shaw S, Reitnauer PJ, Sondel PM. Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens. Human Immunology. 11: 77-97. PMID 6092300 DOI: 10.1016/0198-8859(84)90047-8 |
0.318 |
|
| 1983 |
Sondel PM, Hank JA, Wendel T, Flynn B, Bozdech MJ. HLA identical leukemia cells and T cell growth factor activate cytotoxic T cell recognition of minor locus histocompatibility antigens in vitro. The Journal of Clinical Investigation. 71: 1779-86. PMID 6223050 DOI: 10.1172/Jci110933 |
0.378 |
|
| 1983 |
Sondel PM. Cloning of Human Tumor Stem Cells Journal of Pediatric Hematology/Oncology. 5: 415. DOI: 10.1097/00043426-198324000-00019 |
0.354 |
|
| 1981 |
Sondel PM, Borcherding W, Shahidi NT, Schultz JC, Ganick DJ, Hong R. 878 RECATEGORIZING CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES TO HUMAN T CELLS Pediatric Research. 15: 589-589. DOI: 10.1182/Blood.V57.6.1135.1135 |
0.342 |
|
| 1977 |
Bach FH, Grillot-Courvalin C, Kuperman OJ, Sollinger HW, Hayes C, Sondel PM, Alter BJ, Bach ML. Antigenic requirements for triggering of cytotoxic T lymphocytes. Immunological Reviews. 35: 76-96. PMID 142746 DOI: 10.1111/J.1600-065X.1977.Tb00236.X |
0.314 |
|
| 1976 |
Alter BJ, Grillot-Courvalin C, Bach ML, Zier KS, Sondel PM, Bach FH. Secondary cell-mediated lympholysis: importance of H-2 LD and SD factors. The Journal of Experimental Medicine. 143: 1005-14. PMID 131173 DOI: 10.1084/Jem.143.5.1005 |
0.367 |
|
| 1976 |
Bach FH, Bach ML, Sondel PM. Differential function of major histocompatibility complex antigens in T-lymphocyte activation. Nature. 259: 273-81. PMID 129707 DOI: 10.1038/259273A0 |
0.306 |
|
| 1976 |
Sondel PM, Bach FH. Recognitive specificity of human cytotoxic T lymphocytes. II. The non-recognition of antigens controlled outside the major histocompatibility complex. Tissue Antigens. 7: 173-80. PMID 59401 DOI: 10.1111/J.1399-0039.1976.Tb01048.X |
0.352 |
|
| 1975 |
Sondel PM, Jacobson MW, Bach FH. Pre-emption of human cell-mediated lympholysis by a suppressive mechanism activated in mixed lymphocyte cultures. Journal of Experimental Medicine. 142: 1606-1611. PMID 127827 DOI: 10.1084/Jem.142.6.1606 |
0.37 |
|
| 1975 |
Sheehy MJ, Sondel PM, Bach ML, Wank R, Bach FH. HL-A LD (lymphocyte defined) typing: a rapid assay with primed lymphocytes. Science (New York, N.Y.). 188: 1308-10. PMID 124948 DOI: 10.1126/Science.124948 |
0.327 |
|
| 1973 |
Bach FH, Segall M, Zier KS, Sondel PM, Alter BJ, Bach ML. Cell mediated immunity: separation of cells involved in recognitive and destructive phases. Science (New York, N.Y.). 180: 403-6. PMID 4267047 DOI: 10.1126/Science.180.4084.403 |
0.335 |
|
| Show low-probability matches. |